Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 30;12(8):1846. doi: 10.3390/diagnostics12081846

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Overview of the pathological changes of cardiomyocytes in cardiotoxicity induced by cancer therapies, the resulting morphological and functional changes of the heart, and CMR assessments that have been performed in previous studies. Different CMR parameters may increase (red arrows) or decrease (blue arrows) or be positive (red plus) in cardiotoxicity. LV = left ventricular; LVEF = left ventricular ejection fraction; LVESV = LV end-systolic volume; LVEDV = LV end-diastolic volume; GLS = global longitudinal strain; RVEF = right ventricular ejection fraction; T1WI = T1-weighted imaging; T2WI = T2-weighted imaging; LGE = late gadolinium enhancement; ECV = extracellular volume fraction.